Attorney Docket No.: PR60436USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: John Francis MILLER et al.

Serial No.: 10/568,051 Art Unit: 1796

Filing Date: February 10, 2006 Examiner: Cain, Edward J.

Confirmation No.: 3712

For: Pharmaceutical Metered Dose Inhaler and Methods Relating Thereto

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR §1.97.

		[X]	Copies of the references are attached. Foreign Patent Documents
		[]	Copies of the references were submitted in parent application Serial No (37 CFR §1.98(d))
		[]	A copy of the International Search Report which issued on International Application No is submitted herewith. All of the publications cited in the International Search Report are listed on the attached Form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
	A.	[]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last. (37 CFR §1.97(b))
		OR	
		[X]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 CFR §1.114. (37 CFR §1.97(b)(4))
B.		[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in §1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final Action under §1.113 or (2) a Notice of Allowance under §1.311, whichever occurs first.
		[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Attorney Docket No.: PR60436USw

	[]	Applicant elects the option to pa an Information Disclosure State	ay the fee set forth in 37 CFR §1.17(p) for submission of ment under §1.97(c) (\$180.00).		
C.	[]	Action under §1.113, or a Notice	tement transmitted herewith is being filed after a final e of Allowance under §1.311, whichever occurs first, but fee. Also enclosed is a copy of the International Search ional Publication No		
In accordance with the requirements of 37 CFR §1.97(d):					
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.			
	OR				
	[]	Disclosure Statement was cited counterpart foreign application, no item of information contained	no item of information contained in this Information in a communication from a foreign patent office in a and, to my knowledge after making reasonable inquiry, d in this Information Disclosure Statement was known to 56(c) more than three months prior to the filing of this		
	[]	The petition fee set forth in §1.1	7(i)(1) (\$180.00) is submitted herewith.		
[X] []					
			Respectfully submitted,		
			/Robert J. Smith/		
			Robert J. Smith Attorney for Applicant Registration No. 40,820		
GlaxoS Corpora 5 Moor Researc Telepho	e Drive, ch Triang one: (91	3347			

2